Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial (Q34786700)

4 August 2017

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial (English)

1 reference

4 August 2017

phase II clinical trial

0 references

0 references

0 references

1 reference

1 reference

placebo-controlled trial

1 reference

James O'Beirne

10

0 references

Vincent C Emery

object named as

Vincent C Emery

26

0 references

Andrew Kenneth Burroughs

27

object named as

Andrew K Burroughs

1 reference

4 August 2017

Paul D Griffiths

1

1 reference

4 August 2017

Anna Stanton

2

1 reference

4 August 2017

Erin McCarrell

3

1 reference

4 August 2017

Colette Smith

4

1 reference

4 August 2017

Mohamed Osman

5

1 reference

4 August 2017

Mark Harber

6

1 reference

4 August 2017

Andrew Davenport

7

1 reference

4 August 2017

Gareth Jones

8

1 reference

4 August 2017

David C Wheeler

9

1 reference

4 August 2017

Douglas Thorburn

11

1 reference

4 August 2017

David Patch

12

1 reference

4 August 2017

Claire E Atkinson

13

1 reference

4 August 2017

Sylvie Pichon

14

1 reference

4 August 2017

Paul Sweny

15

1 reference

4 August 2017

Marisa Lanzman

16

1 reference

4 August 2017

Elizabeth Woodford

17

1 reference

4 August 2017

Emily Rothwell

18

1 reference

4 August 2017

Natasha Old

19

1 reference

4 August 2017

Ruth Kinyanjui

20

1 reference

4 August 2017

Tanzina Haque

21

1 reference

4 August 2017

Sowsan Atabani

22

1 reference

4 August 2017

Suzanne Luck

23

1 reference

4 August 2017

Steven Prideaux

24

1 reference

4 August 2017

Richard S B Milne

25

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

4 August 2017

1 reference

4 August 2017

377

1 reference

4 August 2017

9773

1 reference

4 August 2017

1256-1263

1 reference

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Cytomegalovirus reinfections in healthy seroimmune women

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

How we treat cytomegalovirus in hematopoietic cell transplant recipients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Vaccine prevention of maternal cytomegalovirus infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

The case for cytomegalovirus prophylaxis in solid organ transplantation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Progress toward an elusive goal: current status of cytomegalovirus vaccines

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Definitions of cytomegalovirus infection and disease in transplant recipients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

The dynamics of human cytomegalovirus replication in vivo

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

Interrelationships among Quantity of Human Cytomegalovirus (HCMV) DNA in Blood, Donor‐Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for HCMV Disease following Liver Transplantation

26 October 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3075549

9 December 2018

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960136-0

7 January 2021

Human Cytomegalovirus (HCMV) Replication Dynamics in HCMV‐Naive and ‐Experienced Immunocompromised Hosts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960136-0

7 January 2021

Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960136-0

7 January 2021

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960136-0

7 January 2021

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960136-0

7 January 2021

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960136-0

7 January 2021

10.1016/S0140-6736(11)60136-0

Identifiers

DOI

1 reference

4 August 2017

1 reference

4 August 2017

1 reference